GSK's efimosfermin shows potential to improve liver fibrosis in Phase II MASH study
GSK•GSK said Phase 2 findings suggest efimosfermin may improve fibrosis in advanced MASH, including compensated cirrhosis; the drug remains under evaluation in Phase 3 trials.
1. Efimosfermin findings
GSK said Phase 2 findings suggest efimosfermin may improve fibrosis in advanced metabolic dysfunction-associated steatohepatitis, including compensated cirrhosis. The drug remains under evaluation in Phase 3 trials targeting moderate-to-advanced fibrosis and compensated cirrhosis.
2. Other liver data
GSK will present new liver-disease study data at AASLD’s Liver Meeting in Denver from Nov. 5-9, 2026. Presentations will include long-term Phase 3 results for Hibsago in chronic hepatitis B, and examine sustained functional cure after treatment withdrawal, predictors of response and potential retreatment strategies.
